|
[1]KIM BH, CHOI HY, KI M, et al.Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea[J].PLo S One, 2017, 12 (8) :e0182391.
|
|
[2]de BOER YS, van GERVEN NM, ZWIERS A, et al.Genomewide association study identifies variants associated with autoimmune hepatitis type 1[J].Gastroenterology, 2014, 147 (2) :443-452.e5.
|
|
[3]WENG X, HE Y, VISVABHARATHY L, et al.Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease[J].J Hepatol, 2017, 67 (4) :791-800.
|
|
[4]HUANG J, YUAN Q, ZHU H, et al.IL-17C/IL-17RE augments T cell function in autoimmune hepatitis[J].J Immunol, 2017, 198 (2) :669-680.
|
|
[5]QIAN J, MENG Z, GUAN J, et al.Expression and roles of TIPE2in autoimmune hepatitis[J].Exp Ther Med, 2017, 13 (3) :942-946.
|
|
[6]HEALEY R, CORLESS L, GORDINS P, et al.Do anti-smooth muscle antibodies predict development of autoimmune hepatitis in patients with normal liver function-A retrospective cohort review[J].Autoimmun Rev, 2016, 15 (7) :668-672.
|
|
[7]MURATORI P, EFE C, MURATORI L, et al.Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis:A multicentre study[J].Eur J Gastroenterol Hepatol, 2017, 29 (7) :777-780.
|
|
[8]WANG J, MALIK N, YIN M, et al.Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis[J].World J Gastroenterol, 2017, 23 (5) :859-868.
|
|
[9]PUUSTINEN L, HAKKARAINEN A, KIVISAARI R, et al.31Phosphorus magnetic resonance spectroscopy of the liver for evaluating inflammation and fibrosis in autoimmune hepatitis[J].Scand J Gastroenterol, 2017, 52 (8) :886-892.
|
|
[10]BALITZER D, SHAFIZADEH N, PETERS MG, et al.Autoimmune hepatitis:Review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria[J].Mod Pathol, 2017, 30 (5) :773-783.
|
|
[11]BORSSENAD, PALMQVIST R, KECHAGIAS S, et al.Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis:A cohort study[J].Medicine (Baltimore) , 2017, 96 (34) :e7708.
|
|
[12]EFE C, HAGSTROM H, YTTING H, et al.Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J].Clin Gastroenterol Hepatol, 2017, 15 (12) :1950-1956.e1.
|
|
[13]PEISELER M, LIEBSCHER T, SEBODE M, et al.Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J].Clin Gastroenterol Hepatol, 2018, 16 (2) :260-267.e1.
|
|
[14]DESWAL S, SRIVASTAVA A.Role of allopurinol in optimizing thiopurine therapy in patients with autoimmune hepatitis:A review[J].J Clin Exp Hepatol, 2017, 7 (1) :55-62.
|
|
[15]HIRSCHFIELD GM, LIU X, XU C, et al.Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants[J].N Engl J Med, 2009, 360 (24) :2544-2555.
|
|
[16]KAWASHIMA M, HITOMI Y, AIBA Y, et al.Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population[J].Hum Mol Genet, 2017, 26 (3) :650-659.
|
|
[17]QIU F, TANG R, ZUO X, et al.A genome-wide association study identifies six novel risk loci for primary biliary cholangitis[J].Nat Commun, 2017, 8:14828.
|
|
[18]ERICE O, MUNOZ-GARRIDO P, VAQUERO J, et al.MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation[J].Hepatology, 2018, 67 (4) :1420-1440.
|
|
[19]TANG R, WEI Y, LI Y, et al.Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J].Gut, 2018, 67 (3) :534-541.
|
|
[20]BAE HR, LEUNG PS, TSUNEYAMA K, et al.Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance[J].Hepatology, 2016, 64 (4) :1189-1201.
|
|
[21]BAE HR, HODGE DL, YANG GX, et al.The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity[J].Hepatology, 2018, 67 (4) :1408-1419.
|
|
[22]DAHLQVIST G, GAOUAR F, CARRAT F, et al.Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis[J].Hepatology, 2017, 65 (1) :152-163.
|
|
[23]KOWDLEY KV, LUKETIC V, CHAPMAN R, et al.A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J].Hepatology, 2018, 67 (5) :1890-1902.
|
|
[24]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.
|
|
[25]JONES D, BOUDES PF, SWAIN MG, et al.Seladelpar (MBX-8025) , a selective PPAR-δagonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid:A double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[J].Lancet Gastroenterol Hepatol, 2017, 2 (10) :716-726.
|
|
[26]HEGADE VS, KENDRICK SF, DOBBINS RL, et al.Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis:A double-blind, randomised, placebo-controlled, crossover, phase 2a study[J].Lancet, 2017, 389 (10074) :1114-1123.
|
|
[27]HOSONUMA K, SATO K, YAMAZAKI Y, et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol, 2015, 110 (3) :423-431.
|
|
[28]REIG A, SESEP, PARES A.Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response[J].Am J Gastroenterol, 2018, 113 (1) :49-55.
|
|
[29]CHEN S, DUAN W, YOU H, et al.A brief review on prognostic models of primary biliary cholangitis[J].Hepatol Int, 2017, 11 (5) :412-418.
|
|
[30]YANG F, YANG Y, WANG Q, et al.The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis:The additional effect of anti-gp210[J].Aliment Pharmacol Ther, 2017, 45 (5) :733-743.
|
|
[31]CHEUNG KS, SETO WK, FUNG J, et al.Prognostic factors for transplant-free survival and validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid[J].Clin Transl Gastroenterol, 2017, 8 (6) :e100.
|
|
[32]LIN L, PIAO M, JIANG X, et al.Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis?Results from a retrospective study with validation cohort[J].BMJ Open, 2017, 7 (7) :e015304.
|
DownLoad: